BIOMAT Database Logo BIOMAT Database Logo

Bone density in patients receiving long-term anticonvulsant therapy. 1971

J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010018 Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. Adult Rickets,Rickets, Adult
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D011324 Primidone A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite. Desoxyphenobarbital,Primaclone,Apo-Primidone,Liskantin,Misodine,Mizodin,Mylepsinum,Mysoline,Primidon Holsten,Resimatil,Sertan,Apo Primidone
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders

Related Publications

J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy.
November 2009, Archives of Iranian medicine,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
March 2004, Clinical neurology and neurosurgery,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Renal tubular function in patients receiving anticonvulsant therapy: a long-term study.
November 2000, Epilepsia,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Bone changes after long-term anticonvulsant therapy.
December 1973, Neurology India,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Pathophysiology of bone loss in patients receiving anticonvulsant therapy.
February 2004, Epilepsy & behavior : E&B,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy.
December 1990, Archives of internal medicine,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Bone mineral in mentally retarded patients receiving long-term anticonvulsive therapy.
September 1975, Growth,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Calcium metabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy.
March 1978, Canadian Medical Association journal,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids.
June 1994, Chest,
J Linde, and J Molholm Hansen, and K Siersbaek-Nielsen, and V Fuglsang-Fredriksen
Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment.
January 1986, Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie,
Copied contents to your clipboard!